Semaglutide vs Tirzepatide: What’s the Difference?

Semaglutide and tirzepatide are the two most effective pharmacological weight loss treatments currently available — and the comparison between them comes up constantly among patients, physicians, and anyone following the rapidly evolving field of metabolic medicine. Both are weekly injectable GLP-1 receptor agonists. Both produce meaningful weight loss in clinical trials. Both are FDA-approved for chronic weight management.

But they are not the same drug, and the differences between them are clinically significant. This article breaks down the mechanism, the trial data, the side effect profiles, the costs, and the practical considerations that matter when evaluating these two options.

The Core Difference: Single vs. Dual Agonism

The fundamental distinction between semaglutide and tirzepatide is their receptor target profile.

Semaglutide is a GLP-1 receptor agonist — it binds exclusively to GLP-1 receptors. GLP-1 (glucagon-like peptide-1) is a gut hormone that regulates appetite, gastric emptying, and insulin secretion. By activating GLP-1 receptors in the brain, pancreas, stomach, and cardiovascular system, semaglutide reduces hunger, slows digestion, improves blood sugar control, and supports weight loss.

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is a second gut hormone that also influences appetite, fat metabolism, and insulin sensitivity, but through partially distinct pathways. The dual activation is why tirzepatide produces larger effect sizes than semaglutide in head-to-head and comparative trials.

This isn’t simply “more of the same.” GIP and GLP-1 engage different receptor populations in the brain and adipose tissue, and their combined activation appears to produce synergistic rather than merely additive effects on appetite suppression and fat loss. Understanding this distinction is important for setting expectations about magnitude of response.

For a broader overview of how GLP-1 therapy works mechanistically, the guide to GLP-1 therapy covers the full mechanism in plain English.

FDA Approval Status

Both drugs have multiple approved indications, and understanding which approval covers which use matters for insurance coverage and prescribing context.

Table 1 — FDA-approved indications for semaglutide and tirzepatide brand names. The weight management approvals (Wegovy, Zepbound) and diabetes approvals (Ozempic, Mounjaro) are separate prescriptions with different dosing regimens and insurance coverage implications.

Weight Loss: What the Clinical Trials Show

This is where the two drugs diverge most clearly, and where the data is most relevant to most patients considering them for weight management.

Semaglutide: STEP trial program

The STEP 1 trial (2021) is the primary efficacy landmark for semaglutide 2.4 mg (Wegovy) in non-diabetic adults with obesity. Over 68 weeks, participants lost an average of 14.9% of body weight compared to 2.4% with placebo. Approximately one-third achieved 20% or greater weight loss. These results substantially exceeded any prior pharmacological weight loss data and generated the clinical interest that drove the subsequent wave of GLP-1 prescribing.

In STEP 2, which enrolled adults with type 2 diabetes, the average weight loss was lower at 9.6% — consistent with the pattern seen across GLP-1 trials where diabetes blunts the magnitude of weight loss response.

Tirzepatide: SURMOUNT trial program

The SURMOUNT-1 trial (2022) evaluated tirzepatide 5 mg, 10 mg, and 15 mg versus placebo in non-diabetic adults with obesity over 72 weeks. At the highest dose (15 mg), average weight loss was 20.9% of body weight — with more than half of participants achieving at least 20% weight loss. This exceeded semaglutide’s STEP 1 results and established tirzepatide as the most effective pharmacological weight loss option currently available.

SURMOUNT-2 evaluated tirzepatide in patients with type 2 diabetes. Even in this population, the 15 mg dose produced average weight loss of 13.4% — outperforming semaglutide in comparable diabetic populations.

Direct comparison: SURMOUNT-5

The SURMOUNT-5 trial (2025) provided the first large randomized head-to-head comparison of tirzepatide versus semaglutide in adults with obesity without diabetes. Tirzepatide 10–15 mg produced approximately 20% weight loss versus approximately 14% for semaglutide 2.4 mg — a difference of roughly 6 percentage points in favor of tirzepatide that was statistically significant. This trial confirmed that the efficacy gap observed in separate trials is real and not an artifact of different trial populations or designs.

Beyond Weight Loss: Cardiovascular and Metabolic Benefits

Semaglutide: SELECT trial

The SELECT trial (2023) evaluated semaglutide 2.4 mg in over 17,000 adults with obesity and established cardiovascular disease but without diabetes. The trial demonstrated a 20% relative reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, or cardiovascular death — compared to placebo. This was the first large randomized trial to show a cardiovascular mortality benefit from a weight loss drug in non-diabetic patients, and it significantly expanded the clinical case for semaglutide beyond metabolic endpoints.

Tirzepatide: SURMOUNT-MMO

At time of publication, the SURMOUNT-MMO trial evaluating tirzepatide’s cardiovascular outcomes in a similar population is ongoing. Based on the mechanism and early data, positive results are anticipated — but the SELECT-level cardiovascular evidence currently belongs to semaglutide alone.

For blood sugar and HbA1c reduction in type 2 diabetes, tirzepatide outperforms semaglutide in head-to-head trials, consistent with its dual mechanism. The SURPASS-2 trial showed tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 for semaglutide 1 mg — a clinically meaningful difference for patients managing diabetes.

The metabolic health connection to testosterone and hormonal function is discussed in the GLP-1 therapy overview, which covers how significant weight loss can improve hormonal balance in men with obesity-related testosterone suppression.

Side Effect Profiles: How Do They Compare?

Both medications share the same class-level gastrointestinal side effects — nausea, vomiting, diarrhea, constipation, and reduced appetite. These are dose-dependent and most prominent during the escalation phase, which is why both drugs are started at low doses and titrated gradually over several months.

Table 2 — Side effect comparison. Rates are approximate from pivotal trials and may differ across studies. Both drugs share the same class contraindication: personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The key practical difference in tolerability: tirzepatide’s GIP component may partially offset some GI effects of GLP-1 agonism through GIP’s effect on gastric motility — which may explain why some patients who discontinue semaglutide due to GI side effects tolerate tirzepatide better, though this is not consistently demonstrated across all patients.

Both drugs carry an important warning for muscle mass preservation. Weight loss of this magnitude — 15–21% of body weight — includes loss of lean tissue alongside fat. Resistance training and adequate protein intake during treatment are strongly recommended. For men with concerns about muscle preservation in the context of hormonal health, the TRT guide covers how testosterone and body composition interact.

Cost and Access: Real-World Considerations

Which Is Right for You? A Framework for the Decision

The choice between semaglutide and tirzepatide is a clinical decision made with a physician. That said, the decision framework is not arbitrary — several factors meaningfully inform which option is more appropriate.

When semaglutide may be preferred

• Established cardiovascular disease — SELECT trial provides cardiovascular mortality data that tirzepatide’s SURMOUNT-MMO cannot yet match
• When an oral option is important — Rybelsus (oral semaglutide) has no tirzepatide equivalent
• Prior tolerance established — for patients already on Ozempic who are transitioning to a weight management indication
• Insurance coverage specifically for Wegovy when Zepbound is not covered

When tirzepatide may be preferred

• Maximum weight loss is the primary goal — tirzepatide consistently produces larger average weight loss
• Type 2 diabetes with significant HbA1c reduction needed — tirzepatide outperforms semaglutide on glycemic endpoints
• Prior GI intolerance on semaglutide — some patients tolerate tirzepatide better, though this is individual
• Cost — Zepbound’s list price is modestly lower than Wegovy, and Eli Lilly’s self-pay vial program may offer better access for uninsured patients

When the choice doesn’t matter much

For patients who respond well to either drug at therapeutic doses, the practical difference in outcome may be smaller than the trial averages suggest. Some patients achieve 20%+ weight loss on semaglutide; others plateau at 10–12% on tirzepatide. Individual response variability is significant with both drugs, and the “best drug” for a given patient is the one they tolerate well, can access, and sustain long-term. Long-term adherence is the most important predictor of sustained weight loss with either medication.

The broader context of how weight management fits into hormonal and metabolic health — particularly for men with low testosterone alongside obesity — is covered in the weight loss overview.

Frequently Asked Questions

Is tirzepatide always better than semaglutide?

Tirzepatide produces larger average weight loss in clinical trials, including the first head-to-head trial (SURMOUNT-5). But “better” depends on the individual goal. For cardiovascular risk reduction in non-diabetic patients, semaglutide has stronger published evidence (SELECT trial). For maximum weight loss or glycemic control in type 2 diabetes, tirzepatide has the advantage. Individual tolerability, insurance coverage, and physician expertise also factor into the decision — there is no universal answer.

Can I switch from semaglutide to tirzepatide (or vice versa)?

Switching between GLP-1 receptor agonists is possible and does occur clinically, but it requires physician guidance. The switching process involves managing the titration — starting tirzepatide at a low dose regardless of what semaglutide dose you were on — and monitoring for tolerability and response. Switching is sometimes done when a patient has plateaued on one drug, when access or coverage changes, or when GI side effects require an alternative.

Do both drugs cause muscle loss?

Both produce weight loss that includes a proportion of lean mass alongside fat — typically 20–40% of total weight lost is lean tissue in trials without structured exercise. This is a meaningful concern, particularly for men. Resistance training and adequate protein intake (at least 1.2–1.6 g/kg of body weight per day) during treatment significantly reduce the proportion of lean mass lost. Neither drug is muscle-sparing on its own; the lifestyle component matters. Some early data suggests tirzepatide may have a modest lean-mass advantage over semaglutide, but this is not consistently demonstrated and should not be the primary differentiator in the decision.

What happens if I stop either medication?

Both drugs suppress appetite through continuous receptor activation. When discontinued, appetite returns — typically to or near pre-treatment levels — and most patients regain a significant proportion of lost weight over 12–18 months without the medication. The STEP 4 trial (semaglutide) demonstrated that participants who stopped regained approximately two-thirds of lost weight within 48 weeks. Similar patterns are expected with tirzepatide. This underscores that both medications require long-term use for sustained benefit, similar to chronic disease management.

Are compounded versions of these drugs safe?

Compounded semaglutide and tirzepatide became widely available from 503A and 503B compounding pharmacies during FDA shortage periods. They are not FDA-approved finished drug products, meaning they are not subject to the same quality, potency, and sterility standards as the branded versions. Quality varies significantly between compounding pharmacies. Patients using compounded versions should use only licensed 503B outsourcing facilities when possible and discuss the choice with a physician. The FDA has issued guidance on the legal status of compounded GLP-1 analogs as shortages are resolved.

How long does it take for either drug to produce noticeable weight loss?

Most patients notice meaningful appetite reduction within the first 1–4 weeks at initial doses. Visible weight loss — typically 5% of body weight — is often apparent by weeks 12–16 once therapeutic dosing is approached. Maximum weight loss is generally achieved around weeks 60–72 at full doses. The titration phase (first 16–20 weeks) is focused on reaching the therapeutic dose while minimizing GI side effects, not on maximum weight loss — which is why early results are often modest.

Can these medications be used alongside TRT?

There is no established contraindication between GLP-1 receptor agonists and testosterone replacement therapy. For men with both obesity-related testosterone suppression and weight management needs, addressing both conditions can be complementary — significant weight loss improves the hormonal environment by reducing aromatase activity, while testosterone therapy supports lean mass preservation during weight loss. The interaction between these treatments requires physician oversight. The relationship between testosterone, body composition, and metabolic health is discussed in the complete TRT guide.

Does health insurance cover both drugs?

Coverage varies significantly by plan, state, and diagnosis. For the weight management indications (Wegovy, Zepbound), many commercial plans now cover with prior authorization confirming BMI criteria are met — but coverage is far from universal. Medicare Part D currently excludes weight loss drugs. For the diabetes indications (Ozempic, Mounjaro), coverage is considerably more reliable. Manufacturer savings programs can reduce cost to as low as $25/month for commercially insured patients who qualify. Verify with your specific plan and pharmacy before initiating therapy.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
5. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
6. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004
7. U.S. Food & Drug Administration. FDA approves new drug treatment for chronic weight management — Zepbound (tirzepatide). fda.gov — Zepbound approval